EGFR and neoplasm: EGFR-targeted drugs and PD-1 inhibitors can not only reduce the proliferation of thymoma cells by inhibiting the EGFR signaling pathway but also relieve the immunosuppressive microenvironment and improve anti-tumor immune responses.